Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed/ Refractory Non-Hodgkin Lymphoma

NCT05053659 is registered in ClinicalTrials.gov with Paolo Caimi, MD as lead sponsor.

NCT NCT05053659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed/ Refractory Non-Hodgkin Lymphoma
Lead sponsor
Paolo Caimi, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 20, 2022
Completion date
November 30, 2026
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory non-hodgkin lymphoma, relapsed non hodgkin lymphoma